## SEC Form 4

 $\Box$ 

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	OMB APPRO	VAL
40	N I	0005 00

OMB Number:	3235-0287
Estimated average burd	en
hours per response:	0.5

1. Name and Address of Reporting Person*   Moore Terrence O			2. Issuer Name and Ticker or Trading Symbol <u>ACADIA PHARMACEUTICALS INC</u> [ ACAD ]		tionship of Reporting Person(s) to Issuer all applicable) Director 10% Owner Officer (give title Other (specify below) below)		
(Last) (First) (Middle) 3611 VALLEY CENTRE DRIVE, SUITE 300		( )	3. Date of Earliest Transaction (Month/Day/Year) 02/14/2017	EV	P, CHIEF COMMERC	,	
(Street) SAN DIEGO	СА	92130	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	Form filed by One Reporting Person Form filed by More than One Reporting		
(City)	(State)	(Zip)			Person		

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

······································										
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code ( 8)				5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150.4)
Common Stock	02/14/2017		М		87,128	Α	\$19.61	<b>90,759</b> <sup>(1)</sup>	D	
Common Stock	02/14/2017		S <sup>(2)</sup>		89,088	D	<b>\$</b> 39.6863 <sup>(3)</sup>	1,671	D	
Common Stock	02/15/2017		М		1,700	A	\$19.61	3,371	D	
Common Stock	02/15/2017		S <sup>(2)</sup>		1,700	D	\$39.65	1,671	D	
Common Stock	02/16/2017		М		17,421	A	\$19.61	19,092	D	
Common Stock	02/16/2017		М		19,687	A	\$27.2	38,779	D	
Common Stock	02/16/2017		М		29,644	A	\$34.45	68,423	D	
Common Stock	02/16/2017		S <sup>(2)</sup>		66,752	D	\$39.8807(4)	1,671	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned   (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of Deri Sec Acq (A) ( Disp of (I	umber vative urities uired or oosed O) (Instr. and 5)	6. Date Exerc Expiration Da (Month/Day/N	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$19.61	02/14/2017		М			12,747	(5)	08/18/2023	Common Stock	12,747	\$0	7,649	D	
Stock Option (right to buy)	\$19.61	02/14/2017		М			74,381	(5)	08/18/2023	Common Stock	74,381	\$0	55,223	D	
Stock Option (right to buy)	\$19.61	02/15/2017		М			1,700	(5)	08/18/2023	Common Stock	1,700	\$0	53,523	D	
Stock Option (right to buy)	\$19.61	02/16/2017		М			17,421	(5)	08/18/2023	Common Stock	17,421	\$0	36,102	D	
Stock Option (right to buy)	\$27.2	02/16/2017		М			19,687	(6)	03/06/2024	Common Stock	19,687	\$0	13,125	D	
Stock Option (right to buy)	\$34.35	02/16/2017		М			29,644	(7)	03/19/2025	Common Stock	29,644	\$0	90,356	D	

Explanation of Responses:

1. Includes 717, 1,243, 461 and 1,210 shares acquired in November 2014, May 2015, November 2015 and May 2016, respectively, by Mr. Moore under the ACADIA Pharmaceuticals Employee Stock Purchase Plan, as amended.

2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in September 2015, as amended in June 2016.

3. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from \$39.65 to \$39.72 per share, inclusive. The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.

4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from \$39.65 to \$40.38 per share, inclusive. The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.

5. 25% of the shares subject to the Stock Option vested and became exercisable on August 19, 2014. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.

6. 25% of the shares subject to the Stock Option vested and became exercisable on March 7, 2015. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. 7. 25% of the shares subject to the Stock Option vested and became exercisable on March 20, 2016. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.

> <u>/s/ Elizabeth Carter, Attorney-</u> <u>02/16/2017</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.